title: Endogenous oxytocin excites phasic contraction of gallbladder in rabbits through oxytocin receptor.
abstract: These experiments were performed to study the effect of oxytocin (OT) and it's specific receptor on gallbladder motility in rabbits. The fasted New Zealand white rabbits (2.0-2.5 kg) were anaesthetized by urethane (1 g/kg). The gallbladder pressure was recorded continuously to monitor the gallbladder motility. Systemic OT (0.01, 0.02, 0.04 mg/kg, iv) did not affect the gallbladder pressure, but dose-dependently increased the frequency of phasic contraction. Five min after OT administration (0.04 mg/kg, iv), the strength of phasic contraction increased to 0.23 +/- 0.08 mmHg/min (P < 0.01, n = 6). The gallbladder motility returned to normal 15 min later after OT treatment. Intravenous injection of atosiban (0.04 mg/kg, iv), an OT receptor antagonist, decreased the strength of gallbladder phasic contraction but did not affect gallbladder pressure. Pretreatment of atosiban (0.04 mg/kg, iv) completely abolished the systemic OT effect on gallbladder. Vasopressin (VP) (0.1 - 0.5 IU/kg, iv) dose-dependently decrease the gallbladder pressure but did not affect the phasic contraction. MK-329 (0.4 mg/kg, iv), the CCK-A receptor antagonist, L-365, 260 (0.4 mg/kg, iv), the CCK-B receptor antagonist and atropine (0.2 mg/kg, iv), the M receptor antagonist, did not affect the OT effect on gallbladder motility. We suggest that endogenous OT regulates gallbladder phasic contraction through specific OT receptor. This effect is independent of the peripheral CCK and M receptors.
authors.affiliation: Institute of Physiology, Medical School of Shandong University, Jinan, Shandong, PR China. liucy@sdu.edu.cn
authors.forename: Chuan-Yong
authors.initials: CY
authors.lastname: Liu
authors.forename: Jing-Zang
authors.initials: JZ
authors.lastname: Liu
authors.forename: Dong-Ping
authors.initials: DP
authors.lastname: Xie
authors.forename: Pei-Yi
authors.initials: PY
authors.lastname: Liu
authors.forename: Paulus S
authors.initials: PS
authors.lastname: Wang
mesh_terms: D000818:Animals; D001285:Atropine / Q000494:pharmacology; D005260:Female; D016473:Gallbladder Emptying / Q000187:drug effects / Q000502:physiology*; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D010121:Oxytocin / Q000494:pharmacology / Q000502:physiology*; D011817:Rabbits; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014667:Vasopressins / Q000494:pharmacology; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D006727:Hormone Antagonists; D018727:Muscarinic Antagonists; D011949:Receptors, Cholecystokinin; D018045:Receptors, Oxytocin; D014662:Vasoconstrictor Agents; C047046:atosiban; D014667:Vasopressins; D010121:Oxytocin; D001285:Atropine; D014668:Vasotocin